
G. Damaj
11
, P. Feugier
12
, N. Morineau
13
, K. Tarte
14
, F.
Morschhauser
15
, G. Cartron
1
1
CHU Montpellier, Hématologie Clinique, Montpellier, France,
2
IPC,
Hematology, Marseille, France,
3
St Louis, Hematology, Paris, France,
4
CHU, Hematology, Poitiers, France,
5
Oncopole, Hematology, Toulouse,
France,
6
CHB Unicancer, Hematology, Rouen, France,
7
CHU, Hematology,
Nantes, France
8
CHU, Hematology, Rennes, France,
9
CHU, Hematology,
Lyon, France,
10
Oncopole, Pathology, Toulouse, France,
11
CHU,
Hematology, Caen, France,
12
CHU, Hematology, Nancy, France,
13
CHD
Vendée, Hematology, La Roche sur Yon, France,
14
CHU, Pathology,
Rennes, France,
15
CHU, Hematology, Lille, France
Introduction: Relapsed and refractory (R/R) Marginal Zone Lym-
phomas (MZL) treatment remains challenging. Atezolizumab (ATE)
and obinutuzumab (OBI) are monoclonal antibodies acting respec-
tively to inhibit T‐lymphocyte exhaustion or by inducing lymphoma
cells cytotoxicity, whereas venetoclax (VEN) is a small molecule
inhibiting BCL‐2. Combining tumor‐targeted therapies with agents
that enhance anti‐tumor immunity represents an attractive treat-
ment paradigm. This LYSA sponsored multicenter phase 2 trial
(NCT03276468) evaluated ATE, OBI and VEN combination in R/R B‐
cell lymphomas. Herein, we present primary efficacy and safety data
from the MZL cohort.
Methods: Patients ≥18 years with biopsy‐confirmed R/R MZL who
failed at least one line of therapy were eligible. OBI was given IV at
1 g on day (D) 1, 8 and 15 of cycle (C) 1 and on D1 from C2 to C8
every 3 weeks. ATE was given IV, 1.2 g every 3 weeks, started at D2
of C1, then administered at D2 of each cycle for 24 cycles. VEN was
given orally at 800 mg/D at full dose, starting on D8C1 for 24 cycles.
The primary endpoint was the Overall Response Rate (ORR) evalu-
ated by Cheson criteria (CT scan) at the end of induction (EOI) after
8 cycles of ATE, OBI and VEN (M6) or at premature treatment
discontinuation.
Results: At the time of the primary analysis (08 Jan 2021), 20 MZL
patients were enrolled, including 13 nodal MZL, 5 extra‐nodal MZL
(MALT) and 2 splenic MZL. The median follow‐up was 11.9 months
[0.7‐23.6]. Thirteen patients completed induction phase and 11 pa-
tients started maintenance. Baseline characteristics were: median
age, 69 years (52‐83); male, 55.6%; Ann Arbor Stage IV, 100%; bone
marrow infiltration, 38.9%; ≥ 2 extra‐nodal sites, 50%; >2 prior lines
of therapy, 22.2%; refractory to last line of prior regimen, 33.3%. The
ORR at EOI was measured at 66.76% [44.6%‐84.4%], including 16.7%
of CR and 50.0% PR. Best of radiological response rate (BOR) was
77.8% [56.1%‐92.0%] including 22.2% of CR. To date, these re-
sponses seem durable with only 3 reported relapses. Eleven patients
(55%) received the full induction treatment. At the time of analysis, a
median of 8 cycles [1‐8] has been administered. A total of 14 (70%)
pts experienced grade 3–4 adverse event (AE) and no patient expe-
rience an AE that led to discontinuation of any drug. AE of grade 3 or
more reported in at least 10% of patients were neutropenia (55.0%),
thrombocytopenia (20.0%) and anemia (10.0%). Of note, no patient
experienced immune‐related disorder during induction.
Conclusion: ATE, OBI and VEN combo appears to be well tolerated,
with no unexpected toxicity brought by the combination. The ORR at
EOI seems to be comparable to other innovative regiments in this
setting, with durable responses to date.
The research was funded by: Roche, Abbvie
Keywords: Extranodal non‐Hodgkin lymphoma, Indolent non‐
Hodgkin lymphoma, Combination Therapies
Conflicts of interests pertinent to the abstract
C. Herbaux
Consultant or advisory role: Roche, Abbvie
Honoraria: Roche, Abbvie
Educational grants: Roche, Abbvie
146 | ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH
RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL
RESULTS FROM A PHASE 2 STUDY
M. Wang
1
, S. Rule
2
, P. L. Zinzani
3
, A. Goy
4
, O. Casasnovas
5
, S. D.
Smith
6
, G. Damaj
7
, J. K. Doorduijn
8
, T. Lamy
9
, F. Morschhauser
10
, C.
Panizo
11
, B. Shah
12
, A. Davies
13
, R. Eek
14
, J. Dupuis
15
, E. Jacobsen
16
,
A. P. Kater
17
, S. Le Gouill
18
, L. Oberic
19
, T. Robak
20
, P. Jain
21
, R.
Calvo
22
, L. Tao
23
, M. Dlugosz‐Danecka
24
1
MD Anderson Cancer Center, University of Texas, Lymphoma ‐ Myeloma,
Division of Cancer Medicine, Houston, Texas, USA,
2
Plymouth University
Medical School, Hematology, Plymouth, UK,
3
Institute of Hematology
“Seràgnoli” University of Bologna, Experimental, Diagnostic and Specialty
Medicine ‐ DIMES, Bologna, Italy,
4
John Theurer Cancer Center,
Hackensack University Medical Center, Oncology, Hackensack, New
Jersey, USA,
5
CHU Dijon ‐ Hôpital d’Enfants, Hematology, Dijon, France,
6
Fred Hutchinson Cancer Research Center, University of Washington,
Medical Oncology, Seattle, Washington, USA,
7
Institut d’Hématologie de
Basse‐Normandie, Hematology, Caen, France,
8
Erasmus MC, HOVON
Lunenburg Lymphoma Phase I/II Consortium, Hematology, Rotterdam,
Netherlands,
9
CHU de Rennes, Hematology, Rennes, France,
10
CHU Lille,
ULR 7365 ‐ GRITA ‐ Groupe de Recherche sur les formes Injectables et les
Technologies Associées , Hematology, Lille, France,
11
Clínica Universidad
de Navarra, Hematology, Pamplona, Spain,
12
Moffitt Cancer Center,
Malignant Hematology, Tampa, Florida, USA,
13
Cancer Research UK
Experimental Cancer Medicines Centre, University of Southampton Fac-
ulty of Medicine, Medical Oncology, Southampton, UK,
14
Border Medical
Oncology, Medical Oncology, Albury, Australia,
15
Unité Hémopathies
Lymphoïdes, AP‐HP Hôpital Henri Mondor, Hematology, Créteil, France,
16
Dana Farber Cancer Institute, Harvard Medical School, Medical
Oncology, Boston, Massachusetts, USA,
17
Amsterdam University Medical
Center, Amsterdam, on behalf of Hovon, Hematology, Lymphoma and
Myeloma Research , Amsterdam, Netherlands,
18
CHU de Nantes—Hotel
Dieu, Hematology, Nantes, France,
19
Institut Universitaire du Cancer—
Oncopole Toulouse (IUCT‐O), Hematology, Toulouse, France,
20
Coperni-
cus Memorial Hospital, Medical University of Lodz, Hematology, Lodz,
SUPPLEMENT ABSTRACTS
213